Thomas Drames, DO
Critical Care Medicine · Pennington, NJNPI 1003049610
Payments from drug & device makers
Across 480 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Boehringer Ingelheim$521
- Insmed, Inc.$438
- Mylan Specialty L.p.$423
- Genentech USA, Inc.$417
- plus $3K from 32 others
What the payments were for
- Food & beverage$9,67598%
- Education$1742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 166 | $2,815 |
| AstraZeneca | 96 | $1,829 |
| Boehringer Ingelheim | 24 | $521 |
| Insmed, Inc. | 18 | $438 |
| Mylan Specialty L.p. | 22 | $423 |
| Genentech USA, Inc. | 20 | $417 |
| Jazz Pharmaceuticals Inc. | 14 | $379 |
| Amgen | 12 | $304 |
| Harmony Biosciences LLC | 6 | $266 |
| Sanofi | 8 | $246 |
| Regeneron Healthcare Solutions, Inc. | 12 | $238 |
| Electromed, Inc. | 6 | $188 |
| Inspire Medical Systems, Inc. | 4 | $179 |
| Verona Pharma, Inc. | 7 | $161 |
| Axsome Therapeutics, Inc. | 5 | $156 |
| Actelion Pharmaceuticals US, Inc. | 5 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $153 |
| Novartis | 8 | $134 |
| Philips North America LLC | 6 | $108 |
| Vifor Pharma, Inc. | 5 | $93 |
| Mallinckrodt Hospital Products Inc. | 3 | $93 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $80 |
| Grifols USA, LLC | 2 | $69 |
| Advanced Respiratory, Inc | 2 | $56 |
| United Therapeutics Corporation | 3 | $53 |
| Resmed Corp | 2 | $32 |
| Kaleo, Inc. | 2 | $31 |
| Boston Scientific | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Merck | 1 | $26 |
| Masimo Corporation | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Atricure, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,848 in reported general payments places this provider in the 90th percentile of 254 critical care medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 14 | $227,510 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 304 | $215,990 |
| OpsumitMacitentan | 11 | $141,198 |
| Dupixent PenDupilumab | 21 | $83,887 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $35,917 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $24,174 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 38 | $22,800 |
| Spiriva RespimatTiotropium Bromide | 38 | $21,402 |
| SymbicortBudesonide/Formoterol Fumarate | 64 | $15,754 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $13,008 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 24 | $11,397 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 68 | $10,963 |
| Modafinil | 20 | $9,529 |
| EliquisApixaban | 15 | $7,457 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 211 | $5,774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $521 | $283,110114 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $2,815 | $264,915379 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $156 | $141,19811 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,829 | $39,928100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 254 critical care medicine providers in New Jersey.
Other critical care medicine in Pennington
- Fariborz RezaiLivingston$2.4M
- Ronak ShahHackensack$439K
- Eric SztejmanMarlton$231K
- Eric TellerHackensack$217K
- Steven ChangNewark$191K
- Jonathan GalliMarlton$128K
- Keith RoseHackensack$112K
- R Phillip DellingerCamden$74K
- Theodore PlushCamden$63K
- Ricardo VerdinerNew Brunswick$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.